Pharma Focus Asia

Ambry Genetics Announces Integration with FDNA to Advance Precision Medicine

Friday, September 15, 2017

Ambry Genetics Corporation announces integration between their secure AmbryPort 2.0 (AP2) clinician ordering platform and FDNA’s Face2Gene® suite of applications. This integration is expected to dramatically increase and transform the diagnostic power of genetic testing in rare diseases.

Driven to give clinicians the most advanced testing available, Ambry Genetics is a leader in genetic testing for patients with rare diseases. Part of a commitment towards making large-scale genetic testing more affordable and available, Ambry Genetics’ collaboration with FDNA will increase clinicians’ abilities to quickly diagnose and treat patients, while accelerating the rate of scientific discoveries in rare diseases.

Face2Gene’s artificial intelligence and computer vision technology will be used to highlight genetic variants that are highly correlated with disease and the patient’s clinical phenotype. The integration between AP2 and Face2Gene will allow clinicians who are evaluating patients with Face2Gene to securely pass phenotypic information and insights from facial analysis to AP2 to facilitate increased diagnostic yield of molecular interpretation.

“Our goal at Ambry Genetics is to ensure every patient seeking answers is able to find them,” said Laura Panos Smith, MS CGC, Ambry Genetics’ Director of Genetic Specialists. “This technology integration is highlighting relevant syndromes and genetic variants that otherwise may have been missed, and Face2Gene’s deep learning technology learns from each case, ensuring our diagnostic pipeline continues to improve and lead the way for rare genetic diseases.”

Face2Gene is currently used by more than 70% of clinical geneticists worldwide as a means to evaluate syndromes, genes and phenotypes that correlate with patients’ facial and clinical analysis. With this integration, clinicians using Face2Gene can now send clinical genomic insights directly into Ambry Genetics’ bioinformatics pipeline, speeding analysis while improving the rate of diagnoses based on difficult to interpret testing results.

“Bringing FDNA’s artificial intelligence and facial analysis technologies to Ambry Genetics is facilitating a new age in precision medicine,” said Dekel Gelbman, CEO of FDNA. “We expect a dramatic increase in patients who find answers, increased understanding of rare diseases, and increased access for drug developers to create precision therapeutics for this large but underserved patient population.”

Latest Issue
Get instant
access to our latest e-book
MFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Gibco Adherent Kidney Media PanelCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024ISPE Singapore Affiliate Conference & Exhibition 2024Rehab Expo 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024